Ireland-incorporated specialty pharma firm Mallinckrodt Pharmaceuticals (NYSE: MNK) has entered into a definitive agreement under which CVC Capital Partners Fund IX will acquire the company's Therakos photopheresis business.
The deal, which carries a purchase price of $925 million, is subject to customary adjustments and is expected to close in the fourth quarter of this year.
Under the terms of the accord, key employees who work on Therakos will transition with the business and continue supporting the product and its stakeholders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze